Engineered immune cells take on lupus and arthritis in new trial
NCT ID NCT07152223
First seen Nov 01, 2025 · Last updated May 19, 2026 · Updated 31 times
Summary
This study tests a new treatment called CD19-BCMA CAR-T cell therapy for people with connective tissue diseases like lupus, rheumatoid arthritis, and scleroderma. The therapy uses a patient's own immune cells, modified to target and calm the overactive immune system. The main goal is to check safety, but researchers will also see if it improves symptoms. The trial plans to enroll 20 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONNECTIVE TISSUE DISEASES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dongguan Taixin Hospital
RECRUITINGDongguan, Guangdong, 523125, China
Contact Email: •••••@•••••
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.